Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Former club captain Barry Roche leaves Morecambe after 17 years at the Shrimps that spanned both playing and coaching roles.

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

With fewer than 200 trained dermatologists serving Malaysia's 33 million people[1]-just one specialist for every 165,000 ...